case_images: PMC9932914_01
case_images: Electrocardiogram results. ECG was recorded with a set of 12-lead ECG electrodes connected to a central unit software. ECG was taken 8 h (A) or 13 days (B) after the administration of the BNT162b2 messenger RNA (mRNA) (Pfizer-BioNTech) vaccine.
case_images: fmed-10-1071239-g001.jpg
case_images: PMC9932914_01_fmed-10-1071239-g001.jpg
case_images: F1
case_images: MRI results. Cardiac MRI 16 days after the administration of the BNT162b2 messenger RNA (mRNA) (Pfizer-BioNTech) vaccine, 1.5-T MR system. Delayed enhancement sequence in the long axis (A) and short axis (B). Arrows indicate an area of myocardial fibrosis with a non-ischemic pattern in the basal lateral wall, compatible with myocarditis.
case_images: fmed-10-1071239-g002.jpg
case_images: PMC9932914_01_fmed-10-1071239-g002.jpg
case_images: F2
case_images: Nevertheless, the cardiac magnetic resonance image (Figure 2) documented myocardial non-ischemic fibrosis 5 days later, with a cardiac enhancement non-ischemic pattern with diffuse edema.
case_images: PMC9932914_02
case_images: Timeline of the patient's previous cardiac diseases, myocarditis, and pericarditis post-BNT162b2 messenger RNA (mRNA) (Pfizer-BioNTech) vaccine.
case_images: fmed-10-1071239-g003.jpg
case_images: PMC9932914_02_fmed-10-1071239-g003.jpg
case_images: F3
case_images: A timeline of events is presented in Figure 3.